Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

Ozempic, Mounjaro and Wegovy may not be the lightbulb, jet airplane or internet, but their impact is expected to be so ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...

While the outcomes can be positive, Consumer Reports warns there are important considerations, especially for older adults, ...

People taking the weight-loss drug semaglutide could be at a slightly increased risk for a potentially blinding eye co ...

Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...

Even slight weight loss spurred on by cutting-edge GLP-1 drugs can help prevent replacement knees and hips from wearing out, ...

Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared ...